Collectively, although we could not demonstrate that USP39 overexpression contributes to BTZ resistance, our experiments highlight the potential of targeting USP39 as a strategy to overcome BTZ resistance in MM cells. The gene discussed is CASC3; the disease is Miyoshi myopathy.